Hassett J, Parker J
Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Cytometry. 1995 Dec 15;22(4):264-81; discussion 330. doi: 10.1002/cyto.990220403.
Laboratory directors who routinely utilize flow cytometry for at least part of their diagnostic evaluations in leukemias or lymphomas were surveyed by mail. The survey consisted of 12 questions about the flow cytometry procedures used by the laboratory in evaluating leukemias and lymphomas and on the format and content of their official report. It also requested an example of a typical leukemia/lymphoma report and solicited write-in comments about additional important aspects of using flow cytometry to evaluate leukemia and lymphomas not covered by the questionnaire. The goal of the survey, which was sponsored by the Clinical Cytometry Society (CCS), was to document what directors of flow cytometry laboratories currently consider to be the appropriate contents of a clinical leukemia/lymphoma phenotyping analysis and in what manner and detail they report such flow cytometry results to clinicians. The survey indicated that a large number of markers are routinely evaluated to phenotype leukemias (mean = 19) and lymphomas (mean = 16). Light scatter gating, using CD45/14 to monitor the gate selected, is currently employed by a 2:1 ratio over the next most population gating strategy (CD45 vs. 90 degrees LS). Peripheral blood, bone marrow, and lymphoid tissue constitute the majority of clinical specimens evaluated for leukemia and/or lymphoma. Two-color analysis, primarily for surface markers, is currently the standard method for flow cytometry measurements in routine diagnostic studies of leukemia and lymphoma. The official flow cytometry laboratory report is most commonly an individual-lab-generated, paper report form. A discussion of the potential benefits that might result from the development of improved computerized reporting software and from the increased use of antibody-defined, lineage gating is offered. A composite report format is presented that demonstrates the flow measurements and quality control data included in the best of the example clinical reports submitted as part of the survey and considered important by a majority of our survey respondents. The example report is intended to be a basis for further discussion within the flow cytometry community on whether minimum reporting standards for leukemia and/or lymphoma flow cytometry results can and should be developed.
我们通过邮件对那些在白血病或淋巴瘤诊断评估中至少部分常规使用流式细胞术的实验室主任进行了调查。该调查包含12个问题，涉及实验室在评估白血病和淋巴瘤时所采用的流式细胞术程序，以及其官方报告的格式和内容。调查还要求提供一份典型的白血病/淋巴瘤报告示例，并征求关于使用流式细胞术评估白血病和淋巴瘤的其他重要方面的书面意见，这些方面未涵盖在问卷中。这项由临床细胞计量学会（CCS）赞助的调查的目的是记录流式细胞术实验室主任目前认为临床白血病/淋巴瘤表型分析的适当内容，以及他们以何种方式和详细程度向临床医生报告此类流式细胞术结果。调查表明，在白血病（平均 = 19个）和淋巴瘤（平均 = 16个）表型分析中通常会评估大量标志物。与下一种最常用的群体门控策略（CD45与90度侧向散射光[LS]）相比，目前使用CD45/14监测所选门控的光散射门控的比例为2:1。外周血、骨髓和淋巴组织构成了评估白血病和/或淋巴瘤的大多数临床标本。双色分析主要用于表面标志物，目前是白血病和淋巴瘤常规诊断研究中流式细胞术测量的标准方法。流式细胞术实验室的官方报告最常见的是由各个实验室生成的纸质报告形式。文中讨论了改进计算机化报告软件的开发以及增加使用抗体定义的谱系门控可能带来的潜在益处。文中展示了一种综合报告格式，该格式展示了作为调查一部分提交的最佳示例临床报告中包含的流式测量和质量控制数据，并且大多数调查受访者认为这些数据很重要。该示例报告旨在作为流式细胞术领域进一步讨论是否能够以及应该制定白血病和/或淋巴瘤流式细胞术结果的最低报告标准的基础。
